{
    "organizations": [],
    "uuid": "a5dc225652425efb29d86fe914ab2d807046fd26",
    "author": "",
    "url": "https://www.reuters.com/article/brief-genkyotex-cash-and-cash-equivalent/brief-genkyotex-cash-and-cash-equivalents-at-12-5-million-euros-idUSFWN1S2175",
    "ord_in_thread": 0,
    "title": "BRIEF-Genkyotex Cash And Cash Equivalents At 12.5 Million Euros",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 25 (Reuters) - GENKYOTEX SA:\n* CASH AND CASH EQUIVALENTS OF â‚¬12.5 MILLION AS OF MARCH 31ST, 2018, IN LINE WITH EXPECTATIONS\n* COMPANY NOW EXPECTS INTERIM RESULTS FROM PHASE 2 TRIAL OF GKT831 IN PRIMARY BILIARY CHOLANGITIS FALL 2018 AND FINAL RESULTS IN H1 2019\n* BASED ON ANTICIPATED LOWER OPERATING EXPENSES, WE EXPECT COMPANY'S CASH RUNWAY TO NOW EXTEND TO Q3 2019 Source text : bit.ly/2HrtpSt Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-25T18:59:00.000+03:00",
    "crawled": "2018-04-25T19:22:05.025+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "genkyotex",
        "sa",
        "cash",
        "cash",
        "equivalent",
        "million",
        "march",
        "31st",
        "line",
        "expectation",
        "company",
        "expects",
        "interim",
        "result",
        "phase",
        "trial",
        "gkt831",
        "primary",
        "biliary",
        "cholangitis",
        "fall",
        "final",
        "result",
        "h1",
        "based",
        "anticipated",
        "lower",
        "operating",
        "expense",
        "expect",
        "company",
        "cash",
        "runway",
        "extend",
        "q3",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}